Changeflow GovPing Pharma & Drug Safety Nucleic Acid Complex Patent
Routine Notice Added Final

Nucleic Acid Complex Patent

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published patent application EP4032551A1 for a nucleic acid complex, filed by National University Corporation Tokyo Medical and Dental University and Takeda Pharmaceutical Company Limited. The patent covers therapeutic applications in neurological disorders (A61P 25/00) and related formulations. Pharmaceutical and biotechnology companies developing nucleic acid-based therapeutics should review this publication.

What changed

The European Patent Office published patent application EP4032551A1 for a nucleic acid complex, covering IPC classifications including A61K 47/54 (formulations), A61K 48/00 (gene therapy), A61P 25/00 (neurological disorders), and C12N 15/113 (nucleic acid sequences). The application designates all EU member states plus several other European countries. The applicants are National University Corporation Tokyo Medical and Dental University and Takeda Pharmaceutical Company Limited.

No compliance deadline applies to this patent publication notice. Pharmaceutical and biotech companies developing nucleic acid therapeutics should review this publication to assess freedom-to-operate implications and potential licensing opportunities. Competitors should evaluate whether their existing or planned products fall within the scope of these patent claims.

Source document (simplified)

← EPO Patent Bulletin

NUCLEIC ACID COMPLEX

Publication EP4032551A1 Kind: A1 Mar 25, 2026

Applicants

National University Corporation Tokyo Medical
and Dental University, Takeda Pharmaceutical Company Limited

Inventors

YOKOTA, Takanori, NAGATA, Tetsuya, FURUKAWA, Hideki, YOGO, Takatoshi, NAKAGAWA, Yasuo, SASAKI, Shigekazu, TOKUNOH, Ryosuke, SEKI, Tomohiro, HIDAKA, Kosuke, KIKUCHI, Fumiaki, KUBO, Osamu, KASAHARA, Takahito, KOJIMA, Takuto, WANG, Junsi, TOKUNAGA, Norihito

IPC Classifications

A61K 47/54 20170101AFI20231115BHEP A61K 48/00 20060101ALI20231115BHEP A61P 25/00 20060101ALI20231115BHEP A61P 43/00 20060101ALI20231115BHEP C12N 5/079 20100101ALI20231115BHEP C12N 5/10 20060101ALI20231115BHEP C12N 15/113 20100101ALI20231115BHEP A61K 31/713 20060101ALI20231115BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for ChangeBridge: EPO Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4032551A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers Medical device makers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Filing Intellectual Property
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.